Drug intelligence / Profile preview

everolimus + fulvestrant

Development stage: Phase 2
Lead developer: PrECOG
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

A combination therapy consisting of everolimus, an mTOR inhibitor, and fulvestrant, a selective estrogen receptor downregulator (SERD). This combination is used for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women whose disease has become resistant to aromatase inhibitor therapy. The combination works by targeting multiple biological pathways - everolimus inhibits the mTOR signaling pathway while fulvestrant binds, inhibits, and degrades the estrogen receptor.

Brand names: Afinitor + Faslodex
Other names: fulvestrant plus everolimus

Targets

mTOR (Mammalian target of rapamycin kinase)ER (Estrogen receptor)

Beyond the preview

Go deeper on everolimus + fulvestrant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on everolimus + fulvestrant.

Explore the full profile